



Short version of press release from Emotra AB
Gothenburg August 15, 2013

Emotra's method presented at international world congresses

- *In clinical studies a strong relationship between hyporeactivity and risk for suicide has been demonstrated*
- *Emotra has developed, EDOR, ElektroDermal Orientation Reactivity, and objective and quantitative psychophysiological test for the measurement of hyporeactivity*
- *Evaluation of suicide risk is the most challenging problem for the psychiatric care to solve*

That the scientific world, within the field of psychiatry, shows an increased acceptance for Emotra's method, EDOR, is best illustrated by the fact that during the autumn, two of the international congresses within this field, contains oral presentations about research related to the method.

The internationally recognized professor in psychiatry, Wolfgang Kaschka, in Ravensburg, presents his scientific results at the "22nd World Congress on Psychosomatic Medicine, Lisbon, 12-14 September 2013". The title of his speech is; "IS ELECTRODERMAL HYPOREACTIVITY A TRAIT MARKER FOR SUICIDE RISK IN DEPRESSION AND BIPOLAR DISORDER?" Kaschka, is one of the co-authors in the scientific article, in which the results from the follow-up of 783 German patients, in cooperation between German research teams and Lars-Håkan Thorell, the Swedish inventor of EDOR. Lars-Håkan Thorell, presents his method and his own research at the "XXVII World Congress of THE INTERNATIONAL ASSOCIATION FOR SUICIDE PREVENTION, Oslo, 24-28 September 2013". The fact that EDOR is presented at international congresses, suggests that the psychiatric scientists begin to understand how much this can contribute and strengthen suicide prevention.

The psychiatric care has relevant preventive actions and resources to use when risk for suicide has been identified. Unfortunately there are today no accurate methods for the identification of risk patients, with the use of EDOR this difficult diagnostic problem can be solved. The test does not take more than 15 minutes. With necessary preparations, the total time is 30 minutes. The introduction of EDOR as a clinical routine procedure has the potential to substantially reduce the number of suicides and suicide attempts in the world.

For more information, please contact

Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, claes@emotra.se or Lars-Håkan Thorell, Research Manager, Emotra AB, Telephone: +46703263853, lars@emotra.se

Emotra AB is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB, Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, www.emotra.se